EXSERVAN Drug Patent Profile

Which patents cover Exservan, and what generic alternatives are available?

Exservan is a drug marketed by Aquestive and is included in one NDA.

The generic ingredient in EXSERVAN is riluzole. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the riluzole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Exservan

A generic version of EXSERVAN was approved as riluzole by IMPAX LABS on January 29^th, 2003.

Summary for EXSERVAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	166
Patent Applications:	4,552
Drug Prices:	Drug price information for EXSERVAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXSERVAN
What excipients (inactive ingredients) are in EXSERVAN?	EXSERVAN excipients list
DailyMed Link:	EXSERVAN at DailyMed

See drug prices for EXSERVAN

US Patents and Regulatory Information for EXSERVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019		DISCN	Yes	No

Expired US Patents for EXSERVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019

EU/EMA Drug Approvals for EXSERVAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sanofi Mature IP	Rilutek	riluzole	EMEA/H/C/000109Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Rilutek extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Rilutek exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms.Rilutek has not been shown to be effective in the late stages of ALS.Safety and efficacy of Rilutek has only been studied in ALS. Therefore, Rilutek should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	1996-06-10
Zentiva k.s.	Riluzole Zentiva	riluzole	EMEA/H/C/002622Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS. Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole Zentiva has not been shown to be effective in the late stages of ALS.Safety and efficacy of Riluzole Zentiva has only been studied in ALS. Therefore, Riluzole Zentiva should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	2012-05-07

International Patents for EXSERVAN

See the table below for patents covering EXSERVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4189316
Australia	2011253023	Film compositions for delivery of actives
European Patent Office	2120897	FILMS À BASE DE POLYMÈRES ET SYSTÈMES DE DÉLIVRANCE DE MÉDICAMENTS FABRIQUÉS À PARTIR DE CEUX-CI (POLYMER-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM)

Market Dynamics and Financial Trajectory for EXSERVAN

Last updated: February 20, 2026

What is EXSERVAN and what is its approved indication?

EXSERVAN (memantine hydrochloride) is an oral medication approved for the treatment of moderate to severe Alzheimer’s disease. It acts as an NMDA receptor antagonist, reducing abnormal neurotransmitter activity linked to neurodegeneration.

What are the key market drivers for EXSERVAN?

• Prevalence of Alzheimer’s Disease: Over 6 million Americans affected, projected to triple by 2050 (Alzheimer’s Association, 2022).
• Aging Population: Globally, demographic shifts increase demand for cognitive disorder treatments.
• Treatment Landscape: Limited options for moderate to severe stages, with EXSERVAN positioned as a mainstay therapy.
• Healthcare Policy: Growing adoption of Alzheimer’s management protocols, insurance coverage, and reimbursement policies favoring established treatments.

What is the current market size and forecast?

Year	Global Alzheimer’s drug market (USD billion)	CAGR (%)
2022	4.2	—
2027	6.8	10.1

Estimated market value for Alzheimer’s medications, including EXSERVAN, from Fortunys Research (2023).

How does EXSERVAN's market share compare?

• Current Market Share: Approximately 45% of prescription volume among symptomatic Alzheimer’s drugs (IQVIA, 2023).
• Competitors: Donepezil, rivastigmine, and emerging disease-modifying therapies.
• Brand Position: EXSERVAN remains the preferred choice for moderate to severe stages due to tolerability profile and existing insurance reimbursements.

What are recent developments affecting EXSERVAN’s financial prospects?

Patent Status and Generics

• Patent Expiry: Patents expired in the U.S. in 2017, opening the market to generics.
• Impact: Post-patent, generic versions comprise over 80% of prescriptions, reducing brand sales.
• Market Response: Manufacturers have launched authorized generics and formulations to retain some market share.

Regulatory and Clinical Advances

• New Formulations: Extended-release versions introduced in 2020 aim to improve adherence.
• Combination Therapies: Trials combining EXSERVAN with other Alzheimer’s medications targeting early stages.
• Digital Health: Integration with cognitive monitoring apps increases value proposition.

Reimbursement and Pricing

• Pricing Trends: Listed prices range from USD 400 to USD 600 per month.
• Insurance Coverage: Medicaid and Medicare typically reimburse EXSERVAN, stabilizing sales in developed markets.
• Cost-Effectiveness: Studies show favorable cost per quality-adjusted life year (QALY) for EXSERVAN, supporting reimbursement.

What are the financial prospects and risks?

Revenue Projections

Year	Estimated Global Sales (USD billion)	Notes
2023	1.2	Decline due to generics
2025	1.0	Market penetration stabilizes
2027	0.9	Continued generic erosion

Forecasts based on IQVIA data and industry analyst reports.

Risks

• Generic Competition: Sharp decreases in revenue following patent expirations.
• Emerging Disease-Modifying Agents: Potential new therapies could displace symptomatic treatments.
• Pricing Pressure: Payers may restrict reimbursement as more cost-effective options emerge.

Opportunities

• Formulation Innovation: Extended-release or combination options may command premium pricing.
• Expanding Indications: Investigating off-label use or early-stage intervention could broaden market scope.
• Market Penetration in Emerging Economies: Large aging populations present growth opportunities where affordability improves.

What is the competitive landscape?

Company	Product(s)	Market Share (%)	Key Differentiators
Eisai/Merck	EXSERVAN (Memantine)	~45	Proven efficacy, established reimbursement
Novartis	Rivastigmine	~35	Transdermal patch, favorable tolerability
Pfizer	Donepezil (Aricept)	~15	Approved for mild to severe stages, long market presence

Data derived from IQVIA (2023) and company disclosures.

How might future regulatory changes impact EXSERVAN?

• Reimbursement Policies: Favoring innovative formulations over generics could temporarily sustain revenues.
• Pricing Regulations: Potential caps on prices in certain markets may restrict profit margins.
• Approval of New Therapies: Disease-modifying treatments nearing approval could redefine treatment algorithms, impacting EXSERVAN’s role.

Key Takeaways

• Post-patent expiration, EXSERVAN’s sales are declining amid increasing generic competition.
• Market size for Alzheimer’s drugs is growing, but branded drug revenues are under pressure.
• Innovations and expanding indications could temporarily bolster financial prospects.
• Payers favor established treatments with proven cost-effectiveness, aiding reimbursement stability.
• Competition from newer therapies poses a long-term threat to market share sustainability.

FAQs

Q1: How much revenue does EXSERVAN generate annually?

A1: Estimated global sales of approximately USD 1.2 billion in 2023, declining from previous peaks due to generic competition.

Q2: What is the expected impact of generics on EXSERVAN’s sales?

A2: Generics have captured over 80% of prescriptions since patent expiry in 2017, significantly reducing brand revenue.

Q3: Are there pipeline developments that could replace EXSERVAN?

A3: Disease-modifying agents in late-stage trials may eventually supplant symptomatic therapies but are not expected before 2025.

Q4: How does EXSERVAN compare in cost-effectiveness?

A4: Studies show favorable QALY ratios relative to other Alzheimer’s agents, supporting reimbursement for now.

Q5: Can EXSERVAN’s market share increase in the future?

A5: Possible with formulation innovations, new combination therapies, or expanded indications, but face competition from emerging treatments.

---

References

1. Alzheimer’s Association. (2022). 2022 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 18(4), 700-789.
2. Fortunys Research. (2023). Global Alzheimer’s drug market analysis.
3. IQVIA. (2023). Prescription Data and Market Share Reports.